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Vancomycin-resistant Staphylococcus aureus (VRSA) 
infections, which are always methicillin-resistant, are a rare 
but serious public health concern. We examined 2 cases in 
Michigan in 2007. Both patients had underlying illnesses. 
Isolates were vanA-positive. VRSA was neither transmitted 
to or from another known VRSA patient nor transmitted from 
patients to identified contacts.
V
ancomycin continues to be used as a first-line anti-
microbial  agent  for  the  treatment  of  infection  with 
methicillin-resistant Staphylococcus aureus (MRSA). Be-
cause alternative treatments are limited, development of 
resistance to vancomycin can make treatment of MRSA 
infections increasingly difficult. Fortunately, only 7 cas-
es of vancomycin-resistant S. aureus (VRSA) infection, 
which is always methicillin-resistant, have been reported 
in the United States (Table) (1); 5 of these cases occurred 
in Michigan. We report 2 additional cases of VRSA that 
occurred in Michigan in 2007. The Michigan Department 
of Community Health (MDCH) examined the patients’ re-
cords, compared genetic characteristics of isolates, assessed 
possible transmission to contacts, and assessed infection 
control practices at facilities providing patient care.
The Cases
From each patient’s medical records, we collected 
information about demographics and concurrent illness, 
antimicrobial drug history, history of prior MRSA and 
vancomycin-resistant  Enterococcus  spp.  (VRE)  infec-
tions, and VRSA site co-infections. Initial isolate iden-
tification  and  antimicrobial  drug  susceptibility  testing 
were  conducted  by  2  independent  Michigan  hospitals. 
Confirmatory  organism  identification  by  conventional 
biochemical methods and antimicrobial drug susceptibil-
ity testing were performed by MDCH’s Bureau of Labo-
ratories (2,3). Vancomycin resistance is defined as MIC 
>16 µg/mL (4). Isolates were submitted to the Centers for 
Disease Control and Prevention (CDC) for PCR testing 
for van genes, which encode vancomycin resistance, and 
for  genetic  analysis  by  pulsed-field  gel  electrophoresis 
(PFGE) and plasmid restriction digest to compare with 
other VRSA isolates (5–7).
By  following  the  CDC  guide  for  investigating  and 
controlling  VRSA  (8),  we  defined  periods  of  potential 
transmissibility. The length of this period is flexible: start 
date depends on recent culture results, patient care settings, 
and clinical assessment; end date is determined by 2 nega-
tive cultures, which are submitted weekly posttherapy. To 
develop a list of potential patient contacts, we assessed 
healthcare visits, community activities, and personal ac-
quaintances from this period. Contacts were then screened 
for VRSA, starting with persons who had had the most ex-
tensive contact (8). Swabs of bilateral anterior nares and 
open wounds were collected from each contact and spread 
onto blood agar (TSA with sheep blood) and mannitol salt 
agar (both from Remel, Lenexa, KS, USA). Plates were 
incubated for 72 h at 35°C and then for 72 h at room tem-
perature; results were reported as negative when no growth 
occurred after incubation at these conditions. Serial swabs 
were collected from contacts who had ongoing exposure. 
Infection control practices were assessed at all facilities 
that had provided care to each patient.
On October 12, 2007, VRSA and MRSA were cultured 
from a right plantar foot wound of a 48-year-old patient 
(patient 1) who had a history of insulin-dependent diabe-
tes, chronic foot ulcers, and prior concurrent MRSA and 
VRE infections. The patient had recently received vanco-
mycin and ceftriaxone for 7 months to treat osteomyelitis 
of the right metatarsals. The patient’s VRSA infection was 
treated with linezolid and meropenem for 15 weeks. Final 
VRSA-negative  posttreatment  swabs  were  collected  on 
February 26, 2008. The investigation was closed 134 days 
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Table. Vancomycin-resistant Staphylococcus aureus isolates 
detected in the United States, 2002–2006 
Isolate no. State Date isolated
1 Michigan 2002 Jun
2 Pennsylvania 2002 Sep 
3 New York 2004 Mar 
4 Michigan 2005 Feb 
5 Michigan 2005 Oct
6 Michigan 2005 Dec
7 Michigan 2006 Octafter initial VRSA-positive culture (Figure 1).
On December 13, 2007, VRSA, VRE, and Citrobacter 
youngae were cultured from a left plantar foot wound of 
a  54-year-old  patient  (patient  2)  who  had  inadequately 
controlled insulin-dependent diabetes. This patient had no 
documented history of MRSA infection and had recently 
received vancomycin and levofloxacin for 4 weeks to treat 
osteomyelitis of the left metatarsals. The patient’s VRSA 
infection was treated with daptomycin for 6 weeks. Final 
VRSA-negative  posttreatment  swabs  were  collected  on 
March 4, 2008. The investigation was closed 81 days after 
initial VRSA-positive culture (Figure 1).
The VRSA isolates from each patient were highly re-
sistant to vancomycin (each MIC 1,024 µg/mL) but sus-
ceptible to daptomycin, linezolid, quinupristin/dalfopristin, 
rifampin,  tetracycline,  and  tigecycline.  The  isolate  from 
patient 1 was additionally susceptible to chloramphenicol. 
Isolates from both patients were resistant to trimethoprim/
sulfamethoxazole,  whereas  the  7  VRSA  isolates  tested 
previously had been susceptible. VRSA isolates from the 
2 patients were PCR positive for the vanA gene, 1 of the 
7 van genes that encode vancomycin resistance. PFGE re-
sults for both isolates differed from all other US VRSA iso-
lates (data not shown). VRSA isolates from the 2 patients 
reported here had distinct plasmids (Figure 2), and plasmid 
restriction patterns of these isolates differed from the other 
7 US VRSA isolates (7).
The period of potential transmissibility for patient 1 
began October 5, a total of 7 days before the date of posi-
tive culture, because of possible exposures during a recent 
hospitalization; the period ended February 26. The period 
of potential transmissibility for patient 2 began December 
13, the date of positive culture, and ended March 4 (Figure 
1). Contacts for patient 1 were evaluated at 7 locations and 
for patient 2 at 5 locations. For patient 1, a total of 111 
swabs were collected from 75 (99%) of 76 identified con-
tacts; 19 (25%) contacts were positive for S. aureus; 5 (7%) 
were positive for MRSA. For patient 2, a total of 140 swabs 
were collected from 126 (98%) of 128 identified contacts; 
40 (32%) contacts were positive for S. aureus, 13 (10%) 
were positive for MRSA. No contacts of either patient were 
positive  for  VRSA.  No  infection  control  breaches  were 
identified.
Conclusions
These 2 recent cases are consistent with cases reported 
in the review by Sievert et al. (1): each patient had sub-
stantial underlying concurrent conditions that contributed 
to the illnesses, genetic analysis of these isolates indicates 
that VRSA was not transmitted to or from another known 
VRSA  patient,  and  no  identified  transmission  occurred 
from patients to contacts. Also consistent with most previ-
ous cases, each patient reported here had a history of VRE 
and of vancomycin use <3 months before VRSA infection. 
However, patient 2 did not have a documented history of 
MRSA infection or colonization. Given the patient’s his-
tory of diabetes and chronic foot wounds, MRSA might 
have been present but undiagnosed.
Data from the other 7 US cases support the hypoth-
esis that patients at risk for VRSA are co-infected or co-
colonized with VRE and MRSA, which enables transfer of 
the vanA gene from VRE to MRSA in a biofilm environ-
ment, resulting in a VRSA strain. Despite attempts, only 
1 laboratory has reported in vitro transfer of vancomycin 
resistance from VRE to S. aureus, demonstrating that in-
terspecies transfer is not frequent (9). However, in vitro 
transfer of vancomycin resistance from VRSA to S. aureus 
has been demonstrated, reinforcing concerns about poten-
tial intraspecies transfer of vancomycin resistance among 
staphylococci (10).
Although VRSA infection continues to be rare and no 
transmission has been identified, it remains a serious public 
health concern, especially in Michigan where 7 of the 9 US 
cases have occurred. MDCH continues to educate health-
care  providers  about  correct  infection  control  strategies 
(11) and prudent antimicrobial drug use. MDCH’s Bureau 
of Laboratories provides guidance to hospitals on methods 
of  VRSA  detection.  MDCH  field  staff  educate  patients 
and their household contacts about wound care, hand and 
personal hygiene, and the importance of regular monitor-
ing and control of diabetes, a common underlying condi-
tion with VRSA infection. Despite these efforts, questions 
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Figure  1.  Vancomycin-resistant 
Staphylococcus aureus (VRSA) 
culture,  treatment,  and  period 
of potential transmissibility time- 
lines, 2 patients, February 2007– 
April  2008.  Top,  patient  1; 
bottom, patient 2; pos, positive; 
neg, negative.Vancomycin-Resistant Staphylococcus aureus
remain unanswered, including why 7 of the 9 US VRSA 
cases  occurred  in  Michigan.  Before  targeted  prevention 
strategies can be developed, more research is needed to 
improve understanding of the microbiologic, clinical, and 
epidemiologic risk factors for VRSA.
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Figure 2. Restriction enzyme (HindIII) digest of plasmids prepared 
from vancomycin-resistant Staphylococcus aureus (VRSA) isolates 
from 2 patients in Michigan, USA, 2007. Each lane is labeled with 
the VRSA isolate number; lane M, 1-kb molecular marker.